Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Genetic Counseling
Erschienen in: Journal of Genetic Counseling 6/2009

01.12.2009 | Original Research

Women’s Decision Making about Risk-Reducing Strategies in the Context of Hereditary Breast and Ovarian Cancer: A Systematic Review

verfasst von: A. Fuchsia Howard, Lynda G. Balneaves, Joan L. Bottorff

Erschienen in: Journal of Genetic Counseling | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Women who have a mutation in the BRCA1 or BRCA2 genes have up to an 87% lifetime risk of breast cancer and up to a 40% lifetime risk of ovarian cancer. Cancer prevention and early detection strategies are often considered by these women to address this heightened risk. Risk-reducing strategies include risk-reducing mastectomy and oophorectomy, breast and ovarian cancer screening, and chemoprevention. This systematic literature review summarizes the factors and contexts that influence decision making related to cancer risk-reducing strategies among women at high-risk for hereditary breast and ovarian cancer. In the 43 published research articles reviewed, three main types of factors are identified that influence high-risk women’s decisions about risk-reducing strategies: a) medical and physical factors, b) psychological factors and c) social context factors. How these factors operate in women’s lives over time remains unknown, and would best be elucidated through prospective, longitudinal research, as well as qualitative research.
Literatur
Altschuer, A., & Somkin, C. P. (2005). Women’s decision making about whether or not to use breast cancer chemoprevention. Journal of Women's Health, 41(2), 81–95.
Antill, Y., Reynolds, J., Young, M. A., Kirk, J., Tucker, K., Bogtstra, T., et al. (2006). Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. European Journal of Cancer, 42(5), 621–628.CrossRefPubMed
Antiniou, A., Pharoah, P. D., & Narod, S. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72, 1117–1130.CrossRef
Balneaves, L. G., & Long, B. (1999). An embedded decisional model of stress and coping: implications for exploring treatment decision making by women with breast cancer. Journal of Advanced Nursing, 30(6), 1321–1331.CrossRefPubMed
Berchuck, A., Schildkraut, J. M., Marks, J. R., & Futreal, P. A. (1999). Managing hereditary ovarian cancer risk. Cancer, 86(11 Suppl), 2517–2524.CrossRefPubMed
Bober, S. L., Hoke, L. A., Duda, R. B., Regan, M. M., & Tung, N. (2004). Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. Journal of Clinical Oncology, 22(24), 4951–4957.CrossRefPubMed
Botkin, J. R., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., et al. (2003). Genetic testing for BRCA1 mutation: risk-reducing surgery and screening behaviours in women 2 years post testing. American Journal of Medical Genetics, 118A, 201–209.CrossRefPubMed
Bradbury, A. R., Comfort, N. I., Dignam, J. J., Cummings, S. A., Verp, M., White, M. A., et al. (2008). Uptake and timing of bilateral risk-reducing salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine, 10(3), 161–166.CrossRefPubMed
Brain, K., Gravell, C., France, E., Fiander, A., & Gray, J. (2004). An exploratory qualitative study of women’s perceptions of risk management options for familial ovarian cancer: implications for informed decision making. Gynecologic Oncology, 92(3), 905–913.CrossRefPubMed
Claes, E., Evers-Kiebooms, G., Decruyenaere, M., Denayer, L., Boogaerts, A., Philippe, K., et al. (2005). Surveillance behavior and risk-reducing surgery after predictive testing for hereditary breast/ovarian cancer. Behavioral Medicine, 31(3), 93–105.CrossRefPubMed
D’Agincourt-Canning, L. (2006). Genetic testing for hereditary breast and ovarian cancer: responsibility and choice. Qualitative Health Research, 16(1), 97–118.CrossRefPubMed
Easton, D. F., Ford, D., & Bishop, D. T. (1995). Breast and ovarian cancer incidence in BRCA-1 mutation carriers breast cancer linkage consortium. American Journal of Human Genetics, 56, 265–271.PubMed
Fang, C. Y., Miller, S. M., Malick, J., Babb, J., Hurley, K. E., Engstrom, P. F., et al. (2003). Psychosocial correlates of intention to undergo risk-reducing oophorectomy among women with a family history of ovarian cancer. Preventive Medicine, 37(5), 424–431.CrossRefPubMed
Ford, D., Easton, D. F., & Stratton, M. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. American Journal of Human Genetics, 62, 676–689.CrossRefPubMed
Friebel, T. M., Domchek, S. M., Neuhausen, S. L., Wagner, T., Evans, D. G., Isaacs, C., et al. (2007). Bilateral risk-reducing oophorectomy and bilateral risk-reducing mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clinical Breast Cancer, 7(11), 875–882.CrossRefPubMed
Frost, C. J., Venne, V., Cunningham, D., & Gerritsen-McKane, R. (2004). Decision making with uncertain information: learning from women in a high-risk breast cancer clinic. Journal of Genetic Counseling, 13(3), 221–236.CrossRefPubMed
Fry, A., Rush, R., Busby-Earle, C., & Cull, A. (2001). Deciding about risk-reducing oophorectomy: what is important to women at increased risk of ovarian cancer? Preventive Medicine, 33(6), 578–585.CrossRefPubMed
Hallowell, N. (1998). You don’t want to lose your ovaries because you think ‘I might become a man’. Women’s perceptions of prophylactic surgery as a cancer risk management option. Psycho-Oncology, 7, 263–275.CrossRefPubMed
Hallowell, N. (2000). A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psycho-oncology, 9(6), 486–495.CrossRefPubMed
Hallowell, N., Jacobs, I., Richards, M., Mackay, J., & Gore, M. (2001). Surveillance or surgery? A description of the factors that influence high-risk premenopausal women's decisions about risk-reducing oophorectomy. Journal of Medical Genetics, 38(10), 683–691.CrossRefPubMed
Hoogerbrugge, N., Kamm, Y. J. L., Bult, P., Landsbergen, K. M., Bongers, E. M. F. H., Brunner, H. G., et al. (2008). The impact of false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited. Annals of Oncology, 19, 655–659.CrossRefPubMed
Horsman, D., Wilson, B. J., Avard, D., Meschino, W. S., Kim-Sing, C., Plante, M., et al. (2007). Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. Journal of Obstetrics and Gynaecology Canada, 29(1), 45–60.PubMed
Hurley, K. E., Miller, S. M., Costalas, J. W., Gillespie, D., & Daly, M. B. (2001). Anxiety/uncertainty reduction as a motivation for interest in risk-reducing oophorectomy in women with a family history of ovarian cancer. Journal of Women’s Health Gender-Based Medicine, 10(2), 189–199.CrossRefPubMed
Isaacs, C., Peshkin, B. N., Schwartz, M., DeMarco, T. A., Main, D., & Lerman, C. (2002). Breast and ovarian screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Research and Treatment, 71, 103–112.CrossRefPubMed
Kenen, R. H., Shapiro, P. J., Hantsoo, L., Friedman, S., & Coyne, J. (2007). Women with BRCA1 or BRCA2 mutations renegotiating a post-prophylactic mastectomy identity: self-image and self-disclosure. Journal of Genetic Counseling, 16, 789–798.CrossRefPubMed
Kritz-Silverstein, D., Barrett-Connor, E., & Wingard, D. L. (1997). Hysterectomy, oophorectomy and heart disease risk factors in older women. American Journal of Public Health, 87(4), 676–680.CrossRefPubMed
Lerman, C., Hughes, C., Croyle, R. T., Main, D., Durham, C., Snyder, C., et al. (2000). Risk-reducing surgery decisions and surveillance practices one year following BRCA1/2 testing. Preventive Medicine, 31(1), 75–80.CrossRefPubMed
Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G., Seynaeve, C., et al. (2002). One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or risk-reducing surgery). Breast Cancer Research and Treatment, 73(2), 97–112.CrossRefPubMed
Madalinska, J. B., van Beurden, M., Bleiker, M. A., Valdimarsdottir, H. B., Lubsen-Brandsma, L., Massuger, L. F., et al. (2007). Predictors of risk-reducing bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. Journal of Clinical Oncology, 25, 301–307.CrossRefPubMed
McCullum, M., Bottorff, J. L., Kelly, M., Kieffer, S. A., & Balneaves, L. G. (2007). Time to decide about risk-reducing mastectomy: a case series of BRCA1/2 gene mutation carriers. BMC Women’s Health, 7, 3.CrossRefPubMed
McInerney-Leo, A., Hadley, D., Kase, R. G., Giambarresi, T. R., Struewing, J. P., Biesecker, B. B. (2006). BRCA1/2 testing in hereditary breast and ovarian cancer families III: risk perception and screening. American Journal of Medical Genetics, 140(20), 2198–2206.PubMed
Meijers-Heijboer, H., Brekelmans, C. T., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., et al. (2003). Use of genetic testing and risk-reducing mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 21(9), 1675–1681.CrossRefPubMed
Meiser, B., Butow, P., Barratt, A., Friedlander, M., Gattas, M., Kirk, J., et al. (1999). Attitudes toward risk-reducing oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecologic Oncology, 75(1), 122–129.CrossRefPubMed
Meiser, B., Butow, P., Friedlander, M., Schnieden, V., Gattas, M., Kirk, J., et al. (2000). Intention to undergo risk-reducing bilateral mastectomy in women at increased risk of developing hereditary breast cancer. Journal of Clinical Oncology, 18(11), 2250–2257.PubMed
Meiser, B., Butow, P., Price, M., Bennett, B., Berry, G., Tucker, K., et al. (2003). Attitudes to risk-reducing surgery and chemoprevention in Australian women at increased risk for breast cancer. Journal of Women's Health, 12(8), 769–778.CrossRefPubMed
Metcalfe, K. A., Snyder, C., Seidel, J., Hanna, D., Lynch, H. T., & Narod, S. (2005). The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Familial Cancer, 4(2), 97–103.CrossRefPubMed
Metcalfe, K. A., Birenbaum-Carmeli, D., Lubinski, J., Gronwald, J., Lynch, H., Moller, P., et al. (2008). International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 122, 2017–2022.CrossRef
Metcalfe, K. A., Foulkes, W. D., Kim-Sing, C., Ainsworth, P., Rosen, B., Armel, S., et al. (2008). Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clinical Genetics, 73, 474–479.CrossRefPubMed
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266(5182), 66–71.CrossRefPubMed
Miller, S., Fang, C. Y., Manne, S. L., Engstron, P. F., & Daly, M. B. (1999). Decision making about prophylactic oophorectomy among at-risk women: psychological influences and implications. Gynecological Oncology, 75(3), 406–412.CrossRef
Myers, R. (2005). Decision counseling in cancer prevention and control. Health Psychology, 24(4), S71–S77.CrossRefPubMed
Patenaude, A. F. (2005). Genetic testing for cancer: Psychological approaches for helping patients and families. Washington, DC: American Psychological Association.CrossRef
Peshkin, B. N., Schwartz, M. D., Isaacs, C., Hughes, C., Main, D., & Lerman, C. (2002). Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiology, Biomarkers and Prevention, 11(10 Pt 1), 1115–1118.PubMed
Phillips, K. A., Jenkins, M. A., Lindeman, G. J., McLachlan, S. A., McKinley, J. M., Weideman, P. C., et al. (2006). Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clinical Genetics, 70(3), 198–206.CrossRefPubMed
Ray, J. A., Loescher, L. J., & Brewer, M. (2005). Risk-reduction surgery decisions in high-risk women seen for genetic counseling. Journal of Genetic Counseling, 14(6), 473–484.CrossRefPubMed
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van’t Veer, L., Garber, J. E., et al. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. Journal of Clinical Oncology, 22(6), 1055–1062.CrossRefPubMed
Rebbeck, T. R., Kauff, N. D., & Domcheck, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80–87.CrossRefPubMed
Reyna, V. F. (2008). A theory of medical decision making and health: fuzzy trace theory. Medical Decision Making, 28, 850–865.CrossRefPubMed
Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., et al. (2002). Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of Clinical Oncology, 20(5), 1260–1268.CrossRefPubMed
Schmeler, K. M., Sun, C. C., Bodurka, D. C., White, K. G., Soliman, P. T., Uyei, A. R., et al. (2006). Risk-reducing bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstetrics and Gynecology, 108(3 Pt 1), 515–520.PubMed
Stefanek, M. E., Helzlsouer, K. J., Wilcox, P. M., & Houn, F. (1995). Predictors of and satisfaction with bilateral prophylactic mastectomy. Preventive Medicine, 24, 412–419.CrossRefPubMed
Swisher, E. M., Babb, S., Whelan, A., Mutch, D. G., & Rader, J. S. (2001). Risk-reducing mastectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. Journal of Reproductive Medicine, 46(2), 87–94.PubMed
Tiller, K., Meiser, B., Gould, L., Tucker, K., Dudding, T., Franklin, J., et al. (2005). Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer. Psychooncology, 14(4), 249–261.CrossRefPubMed
Tinley, S., Houfek, J., Watson, P., Wenzel, L., Clark, M. B., Coughlin, S., et al. (2004). Screening adherence in BRCA1/2 families is associated with primary physicians’ behavior. American Journal of Medical Genetics, 125A, 5–11.CrossRefPubMed
Unic, I., Verhoef, L. C. G., Stalmeier, P. F. M., & van Daal, V. A. J. (2000). Risk-reducing mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women’s treatment choices and medical-analytic recommendations. Medical Decision Making, 20, 251–262.CrossRefPubMed
Uyei, A., Peterson, S. K., Erlichman, J., Broglio, K., Schmeler, K., Lu, K., et al. (2006). Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing. Cancer, 107(12), 2745–2751.CrossRefPubMed
van Dijk, S., Otten, W., Zoeteweij, M. W., Timmermans, D. R., van Asperen, C. J., Breuning, M. H., et al. (2003). Genetic counselling and the intention to undergo risk-reducing mastectomy: effects of a breast cancer risk assessment. British Journal of Cancer, 88(11), 1675–1681.CrossRefPubMed
van Dijk, S., Otten, W., Timmermans, D. R., van Asperen, C. J., Meijers-Heijboer, H., Tibben, A., et al. (2005). What’s the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. Genetics in Medicine, 7(4), 239–245.CrossRefPubMed
van Dijk, S., van Roosmalen, M. S., Otten, O., & Stalmeier, P. F. M. (2008). Decision making regarding risk-reducing mastectomy: stability of preferences and the impact of anticipated feelings of regret. Journal of Clinical Oncology, 26(14), 2358–2363.CrossRefPubMed
Whittemore, A. S. (1997). Risk of breast cancer in carriers of BRCA gene mutation carriers. New England Journal of Medicine, 337, 788–789.PubMed
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378(6559), 789–792.CrossRefPubMed
Metadaten
Titel
Women’s Decision Making about Risk-Reducing Strategies in the Context of Hereditary Breast and Ovarian Cancer: A Systematic Review
verfasst von
A. Fuchsia Howard
Lynda G. Balneaves
Joan L. Bottorff
Publikationsdatum
01.12.2009
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 6/2009
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-009-9245-9

Weitere Artikel der Ausgabe 6/2009

Journal of Genetic Counseling 6/2009 Zur Ausgabe

Original Research

Attitudes and Practice of Genetic Counselors Regarding Anonymous Testing for BRCA1/2

Abstracts

Presented Abstracts from the Twenty-Eighth Annual Education Conference of the National Society of Genetic Counselors (Atlanta, Georgia, November 2009)

Commentary

A Collaborative Approach to Genetic Testing: A Community Hospital’s Experience

Original Research

Decisions to Seek Healthcare Based on Family Health History Among Urban Appalachian Women

Comment

Response to Robert G. Resta Commentary (Unprepared, Understaffed, and Unplanned: Thoughts on the Practical Implications of Discovering New Breast and Ovarian Cancer Causing Genes)

Original Research

Perceptions of the Concept of Mutation among Family Members of Patients Receiving Outpatient Genetic Services and University Students

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Internistische Arzneimitteltherapie Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise